Verrica Pharmaceuticals Inc.
VRCA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 47.7% | -43.3% | -24.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 63.8% | 85.4% | 92% | 96.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -871% | -1,213.8% | -239.1% | -252.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,012.1% | -1,307.5% | -271.1% | -292.3% |
| EPS Diluted | -14.78 | -14.78 | -7.17 | -12.97 |
| % Growth | 0% | -106.1% | 44.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |